Previous close | 104.67 |
Open | 104.50 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's range | 104.42 - 105.67 |
52-week range | 89.67 - 121.64 |
Volume | |
Avg. volume | 5,680,208 |
Market cap | 182.209B |
Beta (5Y monthly) | 0.75 |
PE ratio (TTM) | 32.63 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.20 (2.10%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | N/A |
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefi